Vir Biotechnology (VIR) News Today $5.62 +0.05 (+0.90%) Closing price 04:00 PM EasternExtended Trading$5.74 +0.12 (+2.05%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Quinn Opportunity Partners LLC Purchases Shares of 65,976 Vir Biotechnology, Inc. (NASDAQ:VIR)Quinn Opportunity Partners LLC acquired a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 65,976 shares of the company's stock, valued at approximateApril 14 at 6:25 AM | marketbeat.comExodusPoint Capital Management LP Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)ExodusPoint Capital Management LP bought a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 246,833 shares of the company's stock, valued at approximatelyApril 11, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Here's WhyVir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Time to Sell?April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Sells 255,118 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)ADAR1 Capital Management LLC reduced its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 79.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 64,067 shares of the company's stock afteApril 9, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De Sells 79,712 SharesApril 7, 2025 | americanbankingnews.comVir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $474,286.40 in StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CEO Backer Marianne De sold 79,712 shares of the business's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. This trade represents a 9.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.April 6, 2025 | marketbeat.comPrudential Financial Inc. Sells 180,800 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)Prudential Financial Inc. lowered its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 42.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 244,569 shares of the company's stock after sellingApril 6, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Reaches New 1-Year Low - Here's What HappenedVir Biotechnology (NASDAQ:VIR) Hits New 1-Year Low - Time to Sell?April 2, 2025 | marketbeat.comStock Movers: Moderna, Tesla, Canada GooseMarch 31, 2025 | bloomberg.comWINTON GROUP Ltd Sells 38,730 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)WINTON GROUP Ltd lowered its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 29.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 92,235 shares of the company's stock after selling 38,730March 31, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Rating of "Moderate Buy" from AnalystsVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has received an average rating of "Moderate Buy" from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buyMarch 30, 2025 | marketbeat.comArtisan Partners Limited Partnership Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)Artisan Partners Limited Partnership acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 918,529 shares of the compaMarch 30, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the companyMarch 28, 2025 | finance.yahoo.comVir Biotechnology (NASDAQ:VIR) Sets New 1-Year Low - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Hits New 1-Year Low - Should You Sell?March 27, 2025 | marketbeat.com49,651 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Fox Run Management L.L.C.Fox Run Management L.L.C. acquired a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 49,651 shares of the company's stock, valued at approximately $364,000. SevMarch 27, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 10.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,252,655 shares of the company's stock after acquiriMarch 23, 2025 | marketbeat.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial ResultsMarch 21, 2025 | prnewswire.com51,967 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Tejara Capital LtdTejara Capital Ltd bought a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 51,967 shares of the company's stock, valued at approximately $3March 19, 2025 | marketbeat.comBank of New York Mellon Corp Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Bank of New York Mellon Corp reduced its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 6.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 604,067 shares of the company's stock after sellingMarch 19, 2025 | marketbeat.comVir enrols first subject in Phase III programme to assess CHD therapyMarch 14, 2025 | finance.yahoo.comVir Biotechnology enrolls first patient in ECLIPSE programMarch 13, 2025 | markets.businessinsider.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement FundNew York State Common Retirement Fund raised its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 163.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,90March 5, 2025 | marketbeat.comHepatitis D Market to Expand Significantly by 2034, States DelveInsight Report | Gilead Sciences, Eiger BioPharma, Janssen R&DMarch 4, 2025 | theglobeandmail.comVir Biotechnology: Catalysts Ahead In Hepatitis And OncologyMarch 4, 2025 | seekingalpha.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned aMarch 4, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Down - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Here's What HappenedMarch 3, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for VIR Q1 Earnings?Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Vir Biotechnology in a report issued on Friday, February 28th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.80) per share for theMarch 3, 2025 | marketbeat.com489,485 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Alta Partners Management Company L.P.Alta Partners Management Company L.P. purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 489,485 shares of the company's stock, valued atMarch 2, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $31.00 at BarclaysBarclays upped their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday.March 1, 2025 | marketbeat.comVir Biotechnology's (VIR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday.March 1, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 8.4% on Insider SellingVir Biotechnology (NASDAQ:VIR) Shares Down 8.4% on Insider SellingFebruary 28, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $67,389.22 in StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the transaction, the executive vice president now owns 79,460 shares of the company's stock, valued at approximately $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.February 28, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday.February 28, 2025 | marketbeat.comBarclays Remains a Buy on Vir Biotechnology (VIR)February 28, 2025 | markets.businessinsider.comVir Biotechnology price target raised to $31 from $26 at BarclaysFebruary 28, 2025 | markets.businessinsider.comQ4 2024 Vir Biotechnology Inc Earnings CallFebruary 27, 2025 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPSVir Biotechnology (NASDAQ:VIR - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%.February 27, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comVir Biotechnology Reports 2024 Financial Results and Strategic AdvancesFebruary 26, 2025 | tipranks.comVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 26, 2025 | businesswire.comVir Biotechnology director George Scangos sells $107,575 in stockFebruary 22, 2025 | investing.comGeorge A. Scangos Sells 10,964 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director George A. Scangos sold 10,964 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the sale, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 20, 2025 | marketbeat.comVir Biotechnology (VIR) to Release Earnings on ThursdayVir Biotechnology (NASDAQ:VIR) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665614)February 20, 2025 | marketbeat.comVir Biotechnology to Participate in TD Cowen 45th Annual Health Care ConferenceFebruary 19, 2025 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini Sells 1,562 SharesVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CAO Brent Sabatini sold 1,562 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $9.15, for a total transaction of $14,292.30. Following the sale, the chief accounting officer now directly owns 28,189 shares in the company, valued at $257,929.35. This trade represents a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.February 15, 2025 | marketbeat.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Sells 1,562 Shares of StockFebruary 15, 2025 | insidertrades.comEmpowered Funds LLC Lowers Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Empowered Funds LLC cut its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 290,626 shares of the company's stock after selling 39,February 15, 2025 | marketbeat.comVir Biotechnology SVP sells shares for $14,291February 14, 2025 | msn.com Remove Ads Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼0.590.80▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼75▲VIR Articles Average Week Remove Ads Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKRO News MRUS News OGN News MOR News SWTX News CRNX News CPRX News PTGX News VKTX News SRRK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIR Stock Free VIR Stock Alerts